Translational Oncology Research International
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Translational Oncology Research International sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Translational Oncology Research International: 11 sponsored US clinical trials, none currently recruiting.
Translational Oncology Research International sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
Translational Oncology Research International ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
NCT01234935
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
NCT00985192
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00769470
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
NCT00591123
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
NCT00203411
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
NCT00203424
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
NCT00217672
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
NCT00203372
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT00138125
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00100854
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
NCT00095706
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 10 |
How the Translational Oncology Research International early-phase archive is shaped
11 indexed studies, none listed as recruiting (0% open); 10 completed (91%).
Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Translational Oncology Research International: archived-pipeline peers nationwide
Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Translational Oncology Research International sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 archived trials
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Translational Oncology Research International page
11 registered trials is a research-attention snapshot, not an endorsement of Translational Oncology Research International or any single study.
- None of Translational Oncology Research International's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Breast Cancer is the condition Translational Oncology Research International studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Translational Oncology Research International pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.